View in EDS

A Phase 2 Trial of Protein Kinase C Iota Inhibition With the Combination of Auranofin and Sirolimus in Patients With Recurrent Ovarian Cancer.

Saved in:
Bibliographic Details
Title: A Phase 2 Trial of Protein Kinase C Iota Inhibition With the Combination of Auranofin and Sirolimus in Patients With Recurrent Ovarian Cancer.
Authors: Jatoi A; Department of Oncology, Mayo Clinic, Rochester, MN., Foster NR; Department of Health Sciences Research, Section of Cancer Center Statistics, Mayo Clinic, Rochester, MN., Wahner Hendrickson A; Department of Oncology, Mayo Clinic, Rochester, MN., Block MS; Department of Oncology, Mayo Clinic, Rochester, MN., Weroha SJ; Department of Oncology, Mayo Clinic, Rochester, MN., Asmus EJ; Department of Health Sciences Research, Section of Cancer Center Statistics, Mayo Clinic, Rochester, MN., Murray NR; Department of Cancer Biology, Mayo Clinic, Jacksonville, FL., Fields AP; Department of Cancer Biology, Mayo Clinic, Jacksonville, FL.
Source: American journal of clinical oncology [Am J Clin Oncol] 2026 May 01; Vol. 49 (5), pp. 238-242. Date of Electronic Publication: 2025 Oct 20.
Publication Type: Journal Article; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8207754 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-453X (Electronic) Linking ISSN: 02773732 NLM ISO Abbreviation: Am J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41114938
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A Phase 2 Trial of Protein Kinase C Iota Inhibition With the Combination of Auranofin and Sirolimus in Patients With Recurrent Ovarian Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Jatoi+A%22">Jatoi A</searchLink>; Department of Oncology, Mayo Clinic, Rochester, MN.<br /><searchLink fieldCode="AU" term="%22Foster+NR%22">Foster NR</searchLink>; Department of Health Sciences Research, Section of Cancer Center Statistics, Mayo Clinic, Rochester, MN.<br /><searchLink fieldCode="AU" term="%22Wahner+Hendrickson+A%22">Wahner Hendrickson A</searchLink>; Department of Oncology, Mayo Clinic, Rochester, MN.<br /><searchLink fieldCode="AU" term="%22Block+MS%22">Block MS</searchLink>; Department of Oncology, Mayo Clinic, Rochester, MN.<br /><searchLink fieldCode="AU" term="%22Weroha+SJ%22">Weroha SJ</searchLink>; Department of Oncology, Mayo Clinic, Rochester, MN.<br /><searchLink fieldCode="AU" term="%22Asmus+EJ%22">Asmus EJ</searchLink>; Department of Health Sciences Research, Section of Cancer Center Statistics, Mayo Clinic, Rochester, MN.<br /><searchLink fieldCode="AU" term="%22Murray+NR%22">Murray NR</searchLink>; Department of Cancer Biology, Mayo Clinic, Jacksonville, FL.<br /><searchLink fieldCode="AU" term="%22Fields+AP%22">Fields AP</searchLink>; Department of Cancer Biology, Mayo Clinic, Jacksonville, FL.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228207754%22">American journal of clinical oncology</searchLink> [Am J Clin Oncol] 2026 May 01; Vol. 49 (5), pp. 238-242. <i>Date of Electronic Publication: </i>2025 Oct 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lippincott+Williams+%26+Wilkins%22">Lippincott Williams & Wilkins </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8207754 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1537-453X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2202773732%22">02773732 </searchLink><i>NLM ISO Abbreviation: </i>Am J Clin Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41114938
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1097/COC.0000000000001263
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 238
    Titles:
      – TitleFull: A Phase 2 Trial of Protein Kinase C Iota Inhibition With the Combination of Auranofin and Sirolimus in Patients With Recurrent Ovarian Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jatoi A
      – PersonEntity:
          Name:
            NameFull: Foster NR
      – PersonEntity:
          Name:
            NameFull: Wahner Hendrickson A
      – PersonEntity:
          Name:
            NameFull: Block MS
      – PersonEntity:
          Name:
            NameFull: Weroha SJ
      – PersonEntity:
          Name:
            NameFull: Asmus EJ
      – PersonEntity:
          Name:
            NameFull: Murray NR
      – PersonEntity:
          Name:
            NameFull: Fields AP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2026 May 01
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1537-453X
          Numbering:
            – Type: volume
              Value: 49
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: American journal of clinical oncology
              Type: main
ResultId 1